Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 126-137

  Xue, Weiwei ^a   Pan, Dabo ^b   Yang, Ying ^a   Liu, Huanxiang ^b   Yao, Xiaojun ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Drug resistance; HCV NS3 4A protease; Molecular dynamics simulations; Substrate envelope; TMC435

Indexed keywords

ALANINE; ARGININE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; SERINE PROTEINASE; SIMEPREVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; GENE MUTATION; HEPATITIS C VIRUS; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; WILD TYPE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84355166397     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.11.007     Document Type: Article

References (46)

1. Accelrys, 2009. Discovery Studio, 2.5; Accelrys: San Diego, CA.
2. Bartenschlager R. The NS3/4A proteinase of the Hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. 1999, 6:165-181.
3. Bayly C.I., Cieplak P., Cornell W., Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97:10269-10280.
4. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., Simmerling C., Wang B., Woods R.J. The amber biomolecular simulation programs. J. Comput. Chem. 2005, 26:1668-1688.
5. Chachra R., Rizzo R.C. Origins of resistance conferred by the R292K neuraminidase mutation via molecular dynamics and free energy calculations. J. Chem.Theory Comput. 2008, 4:1526-1540.
6. Cieplak P., Cornell W.D., Bayly C., Kollman P.A. Application of the multimolecule and multiconformational RESP methodology to biopolymers: charge derivation for DNA, RNA and proteins. J. Comput. Chem. 1995, 16:1357-1377.
7. Cummings M.D., Lindberg J., Lin T.-I., de Kock H., Lenz O., Lilja E., Felländer S., Baraznenok V., Nyström S., Nilsson M., Vrang L., Edlund M., Rosenquist Å., Samuelsson B., Raboisson P., Simmen K. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew. Chem. Int. Ed. 2010, 49:1652-1655.
8. Darden T., York D., Pedersen L. Particle mesh Ewald: an N [center-dot] log(N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98:10089-10092.
9. De Francesco R., Migliaccio G. Challenges and successes in developing new therapies for Hepatitis C. Nature 2005, 436:953-960.
10. Fox T., Kollman P.A. Application of the RESP methodology in the parametrization of organic solvents. J. Phys. Chem. B 1998, 102:8070-8079.
11. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E.; Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, Jr., J. A., Peralta, J. E., Ogliaro, F., Bearpark, M., Heyd, J. J., Brothers, E., Kudin, K. N., Staroverov, V. N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J. C., Iyengar, S. S., Tomasi, J., Cossi, M., Rega, N., Millam, N. J., Klene, M., Knox, J. E., Cross, J. B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., Ochterski, J. W., Martin, R. L., Morokuma, K., Zakrzewski, V. G., Voth, G. A., Salvador, P., Dannenberg, J. J., Dapprich, S., Daniels, A. D., Farkas, Ö., Foresman, J. B., Ortiz, J. V., Cioslowski, J., Fox, D. J., 2009. In Gaussian 09; Gaussian, Inc.: Wallingford, CT.
12. Gohlke H., Kiel C., Case D.A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J. Mol. Biol. 2003, 330:891-913.
13. Gouda H., Kuntz I.D., Case D.A., Kollman P.A. Free energy calculations for theophylline binding to an RNA aptamer: comparison of MM-PBSA and thermodynamic integration methods. Biopolymers 2003, 68:16-34.
14. Guo Z., Prongay A., Tong X., Fischmann T., Bogen S., Velazquez F., Venkatraman S., Njoroge F.G., Madison V. Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. J. Chem. Theory Comput. 2006, 2:1657-1663.
15. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 2011, 55:192-206.
16. Hou T., Zhang W., Case D.A., Wang W. Characterization of domain-peptide interaction interface. A case study on the amphiphysin-1 SH3 domain. J. Mol. Biol. 2008, 376:1201-1214.
17. Johnson C.L., Gale J.M. CARD games between virus and host get a new player. Trends Immunol. 2006, 27:1-4.
18. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79:926-935.
19. Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., Lee M., Lee T., Duan Y., Wang W., Donini O., Cieplak P., Srinivasan J., Case D.A., Cheatham T.E. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33:889-897.
20. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74:2046-2051.
21. Kormos B.L., Benitex Y., Baranger A.M., Beveridge D.L. Affinity and specificity of protein U1A-RNA complex formation based on an additive component free energy model. J. Mol. Biol. 2007, 371:1405-1419.
22. Kwong A.D., McNair L., Jacobson I., George S. Recent progress in the development of selected Hepatitis C virus NS3 4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharm. 2008, 8:522-531.
23. Lenz O., Verbinnen T., Lin T.I., Vijgen L., Cummings M.D., Lindberg J., Berke J.M., Dehertogh P., Fransen E., Scholliers A., Vermeiren K., Ivens T., Raboisson P., Edlund M., Storm S., Vrang L., de Kock H., Fanning G.C., Simmen K.A. In vitro resistance profile of the Hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 2010, 54:1878-1887.
24. Lin C., Lin K., Luong Y.-P., Rao B.G., Wei Y.-Y., Brennan D.L., Fulghum J.R., Hsiao H.-M., Ma S., Maxwell J.P., Cottrell K.M., Perni R.B., Gates C.A., Kwong A.D. In vitro resistance studies of Hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 2004, 279:17508-17514.
25. Lin C., Gates C.A., Rao B.G., Brennan D.L., Fulghum J.R., Luong Y.-P., Frantz J.D., Lin K., Ma S., Wei Y.-Y., Perni R.B., Kwong A.D. In vitro studies of cross-resistance mutations against two Hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 2005, 280:36784-36791.
26. Liu H., Yao X., Wang C., Han J. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Mol. Pharm. 2010, 7:894-904.
27. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., Houghton M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 2007, 6:991-1000.
28. Massova I., Kollman P. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect. Drug Discovery Des. 2000, 18:113-135.
29. Onufriev A., Bashford D., Case D.A. Modification of the generalized born model suitable for macromolecules. J. Phys. Chem. B 2000, 104:3712-3720.
30. Raboisson P., de Kock H., Rosenquist A., Nilsson M., Salvador-Oden L., Lin T.-I., Roue N., Ivanov V., Wähling H., Wickström K., Hamelink E., Edlund M., Vrang L., Vendeville S., Van de Vreken W., McGowan D., Tahri A., Hu L., Boutton C., Lenz O., Delouvroy F., Pille G., Surleraux D., Wigerinck P., Samuelsson B., Simmen K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the Hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 2008, 18:4853-4858.
31. Rizzo R.C., Toba S., Kuntz I.D. A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. J. Med. Chem. 2004, 47:3065-3074.
32. Romano K.P., Ali A., Royer W.E., Schiffer C.A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. USA 2010, 107:20986-20991.
33. Romano K.P., Laine J.M., Deveau L.M., Cao H., Massi F., Schiffer C.A. Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease. J. Virol. 2011, 85:6106-6116.
34. Ryckaert J.-P., Ciccotti G., Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
35. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27:157-162.
36. Simmonds P., Holmes E.C., Cha T.-A., Chan S.-W., McOmish F., Irvine B., Beall E., Yap P.L., Kolberg J., Urdea M.S. Classification of Hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 1993, 74:2391-2399.
37. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., Halfon P., Inchauspé G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.-M., Penin F., Sablon E., Shin-I T., Stuyver L.J., Thiel H.-J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of Hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
38. Sitkoff D., Sharp K.A., Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 1994, 98:1978-1988.
39. Smith R.E.T. Hepatitis C virus therapies. Nat. Rev. Drug Discov. 2006, 5:715-716.
40. Stote R.H., Karplus M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins: Struct. Funct. Bioinform. 1995, 23:12-31.
41. Tibotec, 2011. , accessed Sep 24, 2011. http://www.tibotec.com/news/detail.jhtml?action=view&itemname=news_78.
42. Tsui V., Case D.A. Theory and applications of the generalized born solvation model in macromolecular simulations. Biopolymers 2000, 56:275-291.
43. Duan Y., Wu C., Chowdhury S., Lee M.C., Xiong G., Zhang W., Yang R., Cieplak P., Luo R., Lee T., Caldwell J., Wang J., Kollman P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem 2003, 24:1999-2012.
44. Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25:1157-1174.
45. Welsch C., Domingues F.S., Susser S., Antes I., Hartmann C., Mayr G., Schlicker A., Sarrazin C., Albrecht M., Zeuzem S., Lengauer T. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3/4A protease of the Hepatitis C virus. Genome Biol. 2008, 9:R16.
46. World Health Organization, 2010. Hepatitis C: disease3 burden. World Health Organization, Geneva, Switzerland. , accessed Sep 24, 2011. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.